Introduction
Breast cancer surgery has evolved towards less invasive procedures, yet axillary lymph node dissection (ALND) remains standard for clinically node-positive patients. The TAXIS trial investigates whether tailored axillary surgery (TAS), combined with radiotherapy, can safely replace ALND, focusing on reducing morbidity and improving quality of life.
Tailored Axillary Surgery (TAS)
TAS involves removing biopsied and clipped nodes, sentinel lymph nodes, and palpably suspicious nodes, effectively turning a clinically positive axilla into a clinically negative one. This method aims to reduce the tumor load to a level where radiotherapy can control any remaining disease.
TAXIS Trial Overview
The TAXIS trial is a non-inferiority study comparing TAS followed by radiotherapy to traditional ALND, with disease-free survival as the primary endpoint. Secondary endpoints include morbidity and quality of life, areas where ALND has a known negative impact.
Early Trials and De-escalation
Historical trials have shown that less invasive approaches, such as the sentinel lymph node procedure, can be as effective as ALND in certain patient groups, paving the way for further de-escalation in axillary surgery.
Current Status and Future Directions
As of January 2023, 663 out of 1500 planned patients have been randomized in the TAXIS trial, with accrual completion projected for 2025. The trial's pragmatic design allows for the inclusion of a broad patient population, enhancing the generalizability of its findings.
Conclusion
The TAXIS trial represents a significant step towards de-escalating axillary surgery in clinically node-positive breast cancer patients. By focusing on tailored surgical approaches and the potential of radiotherapy to control residual disease, the trial aims to improve patient outcomes and quality of life without compromising oncological safety.
